Takayuki Kobayashi, Taiki Hakozaki
No abstract text is available yet for this article.
June 13, 2024: Chinese Clinical Oncology
James Yu, Anwaar Saeed
No abstract text is available yet for this article.
June 6, 2024: Chinese Clinical Oncology
Zheng Xuan Ong, Eileen Poon
BACKGROUND: Sarcomas are heterogeneous rare cancers, and while they affect 1% of all adult cancers, they affect 10-20% of adolescents and young adults (AYAs). The 5-year survival rates range between 50-60% but have remained stagnant. While the management of bony sarcomas (BS) usually involves systemic treatment and major morbid surgeries, functional outcomes and quality of life have been largely overlooked. METHODS: A literature search was conducted on PubMed and ScienceDirect using key search terms of "Adolescent and young adult", "AYAO", "bone sarcoma, osteosarcoma, Ewing sarcoma", "functional outcomes" and "health-related quality of life" from 1st January 2003 to 13 March 2023...
June 6, 2024: Chinese Clinical Oncology
Luis Posado-Domínguez, Luis Figuero-Pérez, Alejandro Olivares-Hernández, Luis Chinchilla-Tábora, Patricia Antunez-Plaza, Raquel Rivas-Hernández, María Martín-Galache, Juan Carlos Redondo González, Emilio Fonseca Sánchez
BACKGROUND: Neutrophilia is an increase in the number of neutrophils over 7.5×103 /μL. An increase in leukocytes over 50×103 /μL is called a leukemoid reaction; and when it is associated with a solid tumor, it is considered a paraneoplastic syndrome called paraneoplastic leukemoid reaction (PLR). It is a very rare clinical condition and it is very unusual for it to be associated with carcinosarcoma. We present two cases of a leukemoid reaction observed in the Medical Oncology Department of the University Hospital of Salamanca between May and September 2023...
June 1, 2024: Chinese Clinical Oncology
Xiaolin Cheng, Zhengdong Li, Xiaoqing Jia, Zhiyuan Fan, Qizhi He, Zhigang Zhuang
BACKGROUND: Breast cancer (BRCA) represents a significant health challenge for women globally, with refractory cases showing resistance to current therapeutic strategies. The discovery of novel molecular markers and therapeutic targets is critical for improving outcomes in these patients. The primary aim of this study is to elucidate the role of tumor protein D52 (TPD52) as a novel molecular marker and potential therapeutic target to improve outcomes for BRCA patients. METHODS: Using bioinformatics methods, we screened and evaluated the expression, prognosis, and associated mechanisms of TPD52 in BRCA...
June 1, 2024: Chinese Clinical Oncology
Satoshi Hirano, Hidekazu Takahashi, Sukeyuki Nakamura, Kousei Matsuda, Rintaro Ishikawa, Kei Tamura, Kohei Shikano, Tetsuo Fujita, Hiroyuki Amano, Makoto Nakamura
BACKGROUND: Immune checkpoint inhibitors (ICIs) have become key agents in the treatment of nonsmall cell lung cancer worldwide. However, immune-related adverse events (irAEs) must be addressed to maximize the efficacy of ICIs. Mycobacterium tuberculosis (Mtb) infection is considered as a type of irAE associated with ICIs, but the underlying mechanism is not completely understood. Here, we present a case of pulmonary tuberculosis (TB) that developed during administration of nivolumab and ipilimumab for pulmonary adenocarcinoma that recurred just 2 months after completion of anti-TB treatment...
May 31, 2024: Chinese Clinical Oncology
Lu-Lu Wang, Xiaofei Liu, Xue Tang, Feiqiu Wen, Sixi Liu, Huirong Mai
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) secondary to acute lymphoblastic leukemia (ALL) is a rare disease with poor prognosis, usually attributed to delayed diagnosis. To date, only four cases of ALL developing DLBCL have been reported, while none of them exhibiting central nervous system (CNS) symptoms. CASE DESCRIPTION: Here, we report an unusual case of a 15-year-old boy diagnosed with ALL and treated based on the SCCLG-ALL 2016 protocol. While he was receiving maintenance treatment, the patient developed dizziness and vomiting...
May 29, 2024: Chinese Clinical Oncology
Mateusz Jacek Spałek, Aleksandra Bochyńska, Aneta Borkowska, Paweł Mroczkowski, Bartłomiej Szostakowski
BACKGROUND AND OBJECTIVE: Oncology is increasingly adopting three-dimensional (3D) printing, a method of creating objects through additive manufacturing using various techniques and materials. This technology, divided into conventional 3D printing (using non-biological materials like thermoplastics or titanium) and bioprinting (involving living cells and tissues), has shown potential in surgical planning, implant creation, and radiotherapy. However, despite promising preclinical and clinical applications, its clinical integration faces challenges such as a lack of strong evidence, standardized guidelines, and detailed data on costs and scalability...
May 28, 2024: Chinese Clinical Oncology
Georgios Antonios Margonis, Jaeyun Wang, Dimitris Papakonstantinou, Katharina Beyer, Martin E Kreis, Michael D'Angelica
BACKGROUND: Patients with surgically resectable BRAF-mutated colorectal liver metastases (CRLM) or limited extrahepatic disease constitute a highly selective subgroup among BRAF-mutated patients, characterized by a more indolent disease biology. This is evident in their suitability for surgical resection. However, initial studies from a decade ago presented a discouraging outlook for these patients, citing early, frequent, multifocal recurrences and a very limited median overall survival (OS) of less than two years...
May 28, 2024: Chinese Clinical Oncology
Graziele Silva Paz, Janaina Fernandes
BACKGROUND AND OBJECTIVE: Hematological malignancies (HMs) are a group of neoplasms with hematopoietic origin, currently divided into leukemias, lymphomas and multiple myeloma (MM). Although the advances in the management of HMs, the rate of drug resistance, relapse and refractory disease has been increasing, requiring new therapeutic strategies. In this review, we aim to summarize metformin's antitumoral mechanisms of action and present the latest studies of metformin action in HMs, including in resistant ones...
May 24, 2024: Chinese Clinical Oncology
Alfredo Pinheiro Neto, Henrique Luca Lucchesi, Victor Alexandre Dos Santos Valsecchi, Laura Sterian Ward, Lucas Leite Cunha
Thyroid cancer is the most common endocrine malignancy. It presents a significant challenge despite advances in treatment. Immunotherapy, which harnesses the body's immune system to fight cancer, has emerged as a potential solution. The immune system's interaction with cancer cells follows a complex process involving immune surveillance, equilibrium, and escape. On the other hand, cancer cells develop mechanisms, such as loss of antigenicity and immunogenicity, as well as creating an immunosuppressed tumor microenvironment, to evade immune response...
May 21, 2024: Chinese Clinical Oncology
Madeleine L Hall, Sweet Ping Ng, Umbreen Hafeez, Niall Tebbutt, Marie Sinclair, Farshad Foroudi, Michael Chao, Richard Khor
BACKGROUND AND OBJECTIVE: Palliative radiotherapy (RT) and systemic immuno- or targeted therapy both play significant roles in the treatment of advanced hepatocellular carcinoma (HCC). Concurrent application of these therapies is increasing, however, no guidelines exist regarding the combination of systemic therapy with RT. This narrative review summarises the existing literature reporting toxicity observed after concurrent treatment with RT and immuno- or targeted therapeutic agents commonly used in HCC...
May 19, 2024: Chinese Clinical Oncology
Eric C H Lai, Aidan K Y Ung
BACKGROUND AND OBJECTIVE: Pancreatic cancer is an aggressive malignancy with high mortality. At the time of diagnosis, majority of patients (80-90%) present with either locally advanced unresectable disease or metastatic disease. Even after curative resection, the recurrence rate remains quite high. This article aimed at reviewing the updated management of pancreatic cancer. METHODS: We identified literature by searching Medline and PubMed from January 2010 to June 2023 using the keywords...
May 17, 2024: Chinese Clinical Oncology
Shima Rastegar, Michael Kallen, David Ilan Suster
BACKGROUND AND OBJECTIVE: The tumor microenvironment (TME) is known to exert a significant impact on disease biology and convey prognostic and therapeutic implications in several hematopoietic neoplasms, including diffuse large B-cell lymphoma (DLBCL). Recent discoveries have yielded new information regarding the genetic signatures of the TME. This study aims to review the updates on the cellular markers and genetics of various components of the TME in DLBCL influencing tumor behavior and patients' responses to treatment and discuss the novel treatment modalities available for the patients...
May 11, 2024: Chinese Clinical Oncology
Szymon Piątek, Elżbieta Sarnowska, Joanna Kacperczyk-Bartnik, Halszka Kołaczkowska, Piotr Sobiczewski, Mariusz Bidziński
BACKGROUND AND OBJECTIVE: Hyperthermic intraperitoneal chemotherapy (HIPEC) is still controversial in ovarian cancer (OC) management. Doubts are related mainly to HIPEC effectiveness, but also to its safety. European Society of Medical Oncology and European Society of Gynecologic Oncology do not consider HIPEC as a standard of care. Opposite to European recommendations, National Comprehensive Cancer Network found HIPEC as a treatment option in patients undergoing interval debulking surgery in first-line treatment...
May 11, 2024: Chinese Clinical Oncology
Ahmed Eissa, Stefano Puliatti, Natali Rodriguez Peñaranda, Stefano Resca, Stefano Di Bari, Jessica Vella, Sofia Maggiorelli, Laura Bertoni, Paola Azzoni, Luca Reggiani Bonetti, Davide Campobasso, Stefania Ferretti, Salvatore Micali, Giampaolo Bianchi
BACKGROUND: Histopathological examination, a cornerstone in diagnosing cancer, faces challenges due to its time-consuming nature. This review explores the potential of ex-vivo fluorescent confocal microscopy (FCM) in urology, addressing the need for real-time pathological assessment, particularly in prostate cancer. This systematic review aims to assess the applications of FCM in urology, including its role in prostate cancer diagnosis, surgical margin assessment, and other urological fields...
May 11, 2024: Chinese Clinical Oncology
Gabriel Levin, Walter Henry Gotlieb
Interleukins serve as communicating molecules between cells, mediating key interactions in the tumor microenvironment (TME) between immune cells and non-immune cells. Interleukin-10 (IL-10), a multifunctional cytokine with multiple properties, has been extensively studied in various aspects of immunology and cancer biology. IL-10 is pleiotropic, promotes cytotoxicity, yet inhibits antitumorresponses. In recent years, the role of IL-10 in ovarian cancer (OC) progression and treatment has gained significant scientific attention, elucidating the signaling pathways triggered by IL-10 action...
May 9, 2024: Chinese Clinical Oncology
Salman J Khan, Muhamad Alhaj Moustafa
No abstract text is available yet for this article.
April 18, 2024: Chinese Clinical Oncology
Jiwoo Lee, Carminia Lapuz, Richard Khor, Eddie Lau, Natalie Yang, Adeline Lim, Farshad Foroudi, Sweet Ping Ng
BACKGROUND AND OBJECTIVE: In radiotherapy (RT) for locally advanced cervical cancer, high soft tissue contrast on magnetic resonance imaging (MRI) can ensure accurate delineation of target volumes (TVs) and optimal dose distribution to the RT target and organs at risk (OAR). MRI-guided adaptive RT (MRIgART) is a novel technology that revises RT plans according to anatomical changes occurring throughout the treatment to improve target coverage and minimise OAR toxicity. This review aims to assess the evidence and gaps of MRI use in RT planning and MRIgART in the treatment of cervical cancer, as well as challenges in its clinical implementation...
April 13, 2024: Chinese Clinical Oncology
Wanting Yang, Ming Yin, Jiehong Zhou, Yun Zhu, Beibei Ye, Hui Shi, Bingjie Zhang, Can Yue, Yifeng Zhang, Hongxun Wu, Haohao Li, Xuliang Xia, Shufang Yang, Buyun Ma
BACKGROUND: The current preoperative malignancy risk evaluation for thyroid nodules involves stepwise diagnostic modalities including ultrasonography, thyroid function serology and fine-needle aspiration (FNA) cytopathology, respectively. We aimed to substantiate the stepwise contributions of each diagnostic step and additionally investigate the diagnostic significance of quantitative chromogenic imprinted gene in-situ hybridization (QCIGISH)-an adjunctive molecular test based on epigenetic imprinting alterations...
April 12, 2024: Chinese Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.